BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
BioAge Labs, Inc.NASDAQ: BIOA
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items turns negative
Q1 FY2026 other non-cash items was -$118K, compared with $111K a year earlier. Trailing-twelve-month other non-cash items was -$1.33M.
Context
- Other non-cash items amounted to 12.2% of revenue in FY2025.
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other non-cash items holds near -$118K or moves back toward the trailing-twelve-month quarterly average of -$331.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- (1.1M) USD
- Year-over-year change
- -186.8%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.1M) | -186.8% |
| FY2024 | 2024-12-31 | 1.27M | -92.4% |
| FY2023 | 2023-12-31 | 16.6M | +21463.6% |
| FY2022 | 2022-12-31 | 77K | — |
Other Non-Cash Items vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -650.6% is the lowest of 9, against a peer median of +7.2%.
- Other non-cash items amounts to 12.9% of revenue for BIOA, versus a peer median of 20.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$151.21M CAD | -64.4% | -56.1% | 48.4% | |
| LTM Mar 2026 | $34.41M USD | — | -33.1% | 25.5% | |
| LTM Mar 2026 | CA$28.82M CAD | +170.6% | -40.4% | 9.3% | |
| LTM Mar 2026 | $16.76M USD | +162.2% | +72.9% | — | |
| LTM Mar 2026 | $6.11M USD | -79.0% | -9.2% | 303.1% | |
| LTM Mar 2026 | $5.85M USD | +61.3% | — | 15.1% | |
| LTM Mar 2026 | $3.79M USD | -62.4% | -3.3% | — | |
| LTM Mar 2026 | $3.01M USD | -46.8% | -59.7% | 7.2% | |
| LTM Mar 2026 | $2.88M USD | +124.8% | +1.1% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $1.33M USD | -650.6% | — | 12.9% |
| Peer median (excluding BIOA) | — | +7.2% | -21.1% | 20.3% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.